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Background: Community-acquired pneumonia (CAP) causes considerable worldwide mortality,
but limited data compare the mortality in different regions of the world. Our objective was to
determine if there was a difference in mortality among hospitalized patients with CAP in three
continental regions of the world.
Methods: This was a cohort study of patients hospitalized for CAP between November 2001 and
December 2011 from 70 institutions in 16 countries in US/Canada, Europe and Latin America;
the Community-Acquired Pneumonia Organization (CAPO) international database. The primary
outcome was mortality, and factors of interest included world region, processes of care,
severity of disease, associated pathogen, specific comorbidities, and antimicrobial therapy.
Multivariable logistic regression was performed to adjust for confounding effects on562 3473; fax: þ1 502 562 1147.
.edu (F.W. Arnold).
3 Elsevier Ltd. All rights reserved.
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1102 F.W. Arnold et al.differences in mortality between regions. Patients were analyzed separately based on their
intensive care unit admission status.
Results: A total of 6371 patients were reviewed. Latin America had the highest mortality
(13.3%) followed by Europe (9.1%) and the USA/Canada (7.3%) (P < 0.001 for differences be-
tween regions). Important confounding variables included comorbidities (i.e., congestive
heart failure, cerebrovascular disease), elevated blood urea nitrogen level, antimicrobial ther-
apy (macrolide or fluoroquinolone use), and whether the patient had prior vaccinations (influ-
enza, pneumococcal). After adjustment for confounding variables, estimated differences in
mortality between the three regions were significantly reduced for both patients in the ICU
and the ward.
Conclusions: There was an observed discrepancy in CAP mortality between three world re-
gions. Identified factors that contributed to these differences included incidence of H1N1
infection, elevated BUN, cerebrovascular disease, macrolide use, fluoroquinolone use, and
vaccinations. Treatment regimen (fluoroquinolone and macrolide use) and preventive mea-
sures (vaccinations) were variables that may be modified to help alleviate the differences.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Despite the advancement in the management of
community-acquired pneumonia (CAP), it still has consid-
erable worldwide morbidity and mortality in the United
States of America (US), Canada, Europe and Latin America.
The World Health Organization has reported for decades
that lower respiratory infections are the third leading cause
of death globally.1,2 In the US it is the number one cause of
death due to infectious diseases with a mortality of 20.9/
100,000, and 12.7/100,000 in Canada.3,4 Approximately
half of the $17 billion spent on CAP was for hospitalized
patients.4,5 In Europe, the reported mortality varies
broadly from 4 to 48%. Approximately V5.7 billion is spent
on hospitalized patients with CAP.6 In Argentina and Chile,
multicenter studies reported mortalities of 17% and 15.7%,
respectively.7,8 CAP has a severe morbidity and mortality
globally with an immense dedication of resources.
In an effort to improve outcomes in patients with CAP,
multiple guidelines and severity scores have been created.
These are based partially on factors discussed in the In-
fectious Diseases Society of America/American Thoracic
Society (IDSA/ATS) guidelines and the British Thoracic So-
ciety guidelines for CAP known to be associated with mor-
tality, such as an increased age, the presence of certain co-
morbidities, the need for intensive care, non-adherence
with the IDSA/ATS guidelines for CAP and high severity risk
scores among other factors.9,10 The comparison of CAP
between multiple regions of the world, however, has rarely
been evaluated in one manuscript, especially when
including institutions outside of North America and Europe.
Independent studies evaluate mortality rates for hospi-
talized patients with CAP in individual countries, mostly in
the US and Europe, but differences are not known to be
true or due to study protocol. In other words, in-
terpretations of reported mortality rates are always diffi-
cult as they may result from different causes (varying
enrollment criteria, facilities for different levels of care,
case mix). In order to define whether a difference in mor-
tality exists between regions of the world, a single study is
needed which examines multiple regions. It is important to
define if a change in mortality exists, and to identify anymodifiable reasons so that those involved in healthcare in a
certain region may improve the mortality of patients with
CAP.
The primary objective of this study was to define if there
was a difference in mortality among patients with CAP in
three continental regions of the world. Secondary objec-
tives were to determine to what degree factors, such as
comorbidities, severity of disease, processes of care and
antimicrobial use, varied in those regions that might
explain a difference.
Materials and methods
Study design and population
This was a cohort study of the Community-Acquired Pneu-
monia Organization (CAPO) international database from
November 1, 2001 to December 30, 2011 including patients
18 years of age or greater who were selected by partici-
pating center primary investigators from a list of hospital-
ized patients with CAP. The organization has members in 16
countries representing 70 institutions that contributed to
the database. Local Institutional Review Board permission
was requested, and consent was waived because this study
was retrospective and observational. CAPO has been
described previously,11 and the case report form as well as
other details of CAPO may be reviewed at www.caposite.
com.
Study definitions
Study regions were defined as US/Canada (region I), Europe
(region II), and Latin America (region III). CAP was defined
previously.12 Mortality was defined as overall 28-day in-
hospital mortality. High severity of disease included pa-
tients with a pneumonia severity index (PSI) risk class of IV
or V. Data collected included patient demographics,
severity of disease, in-hospital mortality, antimicrobial
therapy, and pathogen identification in each region. Five
process of care variables were reviewed including having
had a pneumococcal or influenza vaccination prior to
CAP mortality differences in three world regions 1103hospitalization, receiving antimicrobials within 8 h of
arriving to the emergency department, having an oxygen-
ation status evaluation with a pulse oximeter or an arterial
blood gas, and having blood cultures taken.Statistical analyses
Descriptive analyses were performed to characterize the
patient populations in each region. P-Values for differences
between regions were calculated using either the c2 sta-
tistic (for categorical variables) or analysis of variance (for
continuous variables). A P-value of <0.05 was considered
statistically significant. Differences in in-hospital mortality
between regions were analyzed using logistic regression,
stratified by intensive care unit (ICU) status. Multivariable
logistic regression was performed to assess the impact of
confounding variables on any observed differences in mor-
tality between regions. The purposeful selection algorithm,
which utilizes a combination of statistical significance
(P  0.25 for inclusions and P  0.1 for retention) and
confounding impact (15% change on other beta co-
efficients) was used to identify the important covariates to
include in the final model.13 Based on our previous expe-
rience, covariates that were found to be associated with
mortality were initially selected.11,14 These covariates
included all of the factors in Tables 1 (except ‘age’, ‘total
comorbidities’, and ‘hypoxia’) and in 4; however, among
the antimicrobial regimens only ‘macrolide’, ‘fluo-
roquinolone’, and ‘b-lactam alone’ were included, to avoid
instability of parameter estimates due to multicollinearity.
Antimicrobial use was adjusted for CAP severity. Interac-
tion with disease severity was checked to determine if
fluoroquinolone or macrolide use was associated with
higher mortality for some risk factors and not others.
Interaction with region was also evaluated. Additionally, a
covariate for infection by H1N1 (Table 3) was constructed
and evaluated for inclusion in the multivariable model.
Lastly, to determine the individual confounding effect of
each retained covariate in the final multivariable model,
each variable was added separately to a model with region
alone. The percent difference in the odds ratio due to
including the covariate was calculated as
(ORadjusted  ORunadjusted)/(ORunadjusted  1) * 100%, where
ORunadjusted was the unadjusted odds ratios between re-
gions, and ORadjusted was the adjusted odds ratios between
regions after including the covariate.15
To account for missing values, we used multiple impu-
tation to create completed datasets with missing informa-
tion filled-in.16,17 Multiple imputation is an effective
strategy to prevent biased estimates resulting from pa-
tients who are missing critical covariate information form-
ing a selective subsample of the entire sample.16 All
evaluated variables were used to construct ten imputed
datasets, and variable selection was conducted using the
purposeful selection algorithm separately in each imputed
dataset. Variables were retained if they were included in a
majority of the models fitted to each imputed dataset. A
final multivariable model using the retained variables was
fit to each imputed dataset, and the resulting parameter
estimates were averaged. Standard errors were based onthe imputation-corrected varianceecovariance matrix,
using R package Hmisc.18Results
A total of 6371 patients were reviewed. The demographics
for each region are listed in Table 1. Latin America had the
lowest prevalence of every comorbidity that was measured.
It also had the highest proportion of patients with tachyp-
nea, hypertension, abnormal temperature and hyper-
natremia. Seven variables had missing information;
respiratory rate e 288 (4.5%), heart rate e 15 (0.2%), pH e
1449 (22.7%), BUN e 324 (5.1%), glucose e 104 (1.6%), he-
matocrit 28 (0.4%), and hypoxia e 79 (1.2%).
For each region, the fewest number of patients were in
Risk Class I while the highest number were in Risk Class IV.
(Table 2) When comparing the severity of disease between
regions, Europe had the fewest low risk class patients, and
the greatest number of high risk class patients.
Forty separate organisms were identified from respira-
tory specimens of 1753 patients. A total of 171 patients had
two organisms identified. The most frequent 12 organisms
are listed in Table 3. Streptococcus pneumoniae was the
most common pathogen. Staphylococcus aureus was most
common in the US/Canada, atypical pathogens were most
common in Europe, and influenza virus was most common in
Latin America (laboratory confirmed influenza A, presumed
2009 H1N1).
Among the five process of care variables measured,
obtaining blood cultures was performed more frequently in
the US/Canada compared to the other two regions. (Table
4) Latin America prescribed antimicrobials within
8 h more often than the other two regions, but Latin
America also had the largest proportion of patients who
were missing this information (29%, see footnote for Table
4). Regarding treatment strategies, Latin America used a
b-lactam alone most often (41% overall and 30% in the ICU),
followed by Europe (16% overall and 13% in the ICU) and
then the US/Canada (8% overall and 8% in the ICU). Latin
America also had the lowest proportion of patients pre-
scribed a fluoroquinolone or a macrolide. Overall, patients
in Latin America were less frequently immunized or pre-
scribed a macrolide or a fluoroquinolone (Table 4).
The US/Canada had the lowest overall mortality (7.3%),
followed by Europe (9.1%) and Latin America (13.3%) (Table
5). Mortality, even in the lower risk classes, was signifi-
cantly higher for Latin America (Fig. 1). In Latin America,
the mortality was 4.7% and 4.5% for PSI risk classes I and II,
respectively. Table 5 provides mortality rates by treatment
regimen, separately by region and ICU/ward. Two general
observations can be gleaned from the table. First, therapy
with a macrolide or fluoroquinolone was advantageous to
use with a b-lactam alone for patients on the ward (Table
5). This advantage for macrolide use was also present for
patients in the ICU. Interestingly, however, a fluo-
roquinolone did not provide the same protection in the ICU
against in-hospital mortality that was observed with mac-
rolide use. The second general observation is that the same
overall mortality trend (lowest in the US/Canada and
highest in Latin America) was present irrespective of anti-
microbial region, with only a few exceptions. When
Table 1 Demographics of 6371 patients with community-acquired pneumonia in three regions of the world. The numbers of
patients are listed with the corresponding proportion in parentheses.
Region I Region II Region III Pa
US/Canada Europe Latin America
n Z 1834 n Z 2861 n Z 1676
Male 1285 (70) 1654 (58) 880 (53) <0.001
Mean age 64.2  16.9 70.8  17.4 61.2  20.0 <0.001
COPD 657 (36) 713 (25) 319 (19) <0.001
Diabetes mellitus 463 (25) 481 (17) 232 (14) <0.001
Cerebrovascular disease 191 (10) 637 (22) 132 (8) <0.001
Parapneumonic effusion 391 (21) 701 (25) 324 (19) <0.001
Congestive heart failure 374 (20) 510 (18) 299 (18) 0.059
Liver disease 74 (4) 166 (6) 45 (3) <0.001
Renal disease 251 (14) 294 (10) 121 (7) <0.001
Nursing home residence 125 (7) 194 (7) 65 (4) <0.001
Neoplastic disease 224 (12) 325 (11) 123 (7) <0.001
Total comorbiditiesb 1421 (77) 2084 (73) 1060 (63) <0.001
Altered mental status 209 (11) 454 (16) 269 (16) <0.001
Respiratory rate  30 breaths/minc 298 (16) 438 (17) 497 (30) <0.001
Systolic blood pressure < 90 mmHg 90 (5) 130 (5) 134 (8) <0.001
Temperature <35 C or 40 C 64 (3) 220 (8) 196 (12) <0.001
Heart rate  125 beats/minc 310 (17) 267 (9) 172 (10) <0.001
pH < 7.35c 118 (8) 132 (6) 102 (8) 0.173
BUN > 30 mg/dLc 356 (19) 1011 (38) 395 (25) <0.001
Sodium < 130 mmol/L 119 (6) 181 (6) 112 (7) 0.664
Glucose >250 mg/dLc 109 (6) 187 (7) 115 (7) 0.408
Hematocrit < 30% 188 (10) 193 (7) 148 (9) <0.001
Hypoxiac, d 687 (38) 1226 (43) 575 (35) <0.001
COPD Z chronic obstructive pulmonary disease; HIV Z human immunodeficiency virus.
a P Values for differences between regions were calculated using either the c2 statistic (for categorical variables) or analysis of
variance (for continuous variables).
b Patients with at least one comorbidity.
c Data were missing for the following variables: respiratory rate (288), heart rate (15), pH (1449), BUN (324), glucose (104), hematocrit
(28), and hypoxia (79).
d PaO2 < 60 mmHg or O
2 sat < 90%.
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tality was highest irrespective of the region (Table 5).
The increase in mortality risk associated with fluo-
roquinolone use in the ICU was exactly the same after
adjustment for PSI risk class (unadjusted OR Z 1.35, 95%Table 2 The severity of disease of subjects with
community-acquired pneumonia according to the pneu-
monia severity index.
Region I Region II Region III P
US/Canada Europe Latin America
n Z 1834 n Z 2861 n Z 1676
No. (%) No. (%) No. (%)
PSI risk class
I 182 (10) 223 (8) 212 (13) <0.001
II 295 (16) 353 (12) 331 (20)
III 402 (22) 490 (17) 360 (21)
IV 662 (36) 1127 (39) 505 (30)
V 293 (16) 666 (23) 268 (16)confidence interval (CI) 0.94e1.95; adjusted OR Z 1.35,
95% CI 0.93e1.96). The interaction terms between fluo-
roquinolone use and disease severity in relation to mor-
tality was also non-significant (P Z 0.27). The interaction
between fluoroquinolone use and mortality by region indi-
cated that while fluoroquinolone use was associated with
higher mortality in the ICU for US/Canada (ORZ 2.34, 95%
CI 1.20e4.77) and Latin America (OR Z 1.66, 95% CI
0.94e2.95), there was no association between fluo-
roquinolone use and mortality for European patients
(OR Z 0.87, 95% CI 0.38e1.99). Fluoroquinolone use was
not higher among more severe cases in the US/Canada
relative to Europe (P Z 0.74 for association). Overall, flu-
oroquinolone use in the ICU was not significantly lower in
Europe (44%) compared to the US/Canada (51%, P Z 0.17),
though it was significantly lower in Latin America (25%,
P < 0.001).
For macrolide use in the ICU, the overall odds ratio for
mortality was 0.45, 95% CI 0.31e0.66. This did not change
dramatically after adjustment for disease severity
(OR Z 0.49, 95% CI 0.33e0.72). Additionally, there was no
interaction between macrolide use and disease severity in
relation to mortality (P Z 0.33). The strongest protective
Table 3 The etiology of community-acquired pneumonia in 1753 patients from three regions of the world who had a positive
respiratory specimen culture; 171 patients had coinfection.
Region I Region II Region III Total
US/Canada Europe Latin America
n Z 529 n Z 680 n Z 544 n Z 1753
No. (%)a No. (%)a No. (%)a No.
Etiology
Streptococcus pneumoniae 237 (41) 351 (48) 145 (26) 733
Pandemic 2009 (H1N1) influenza A
b 27 (5) 49 (7) 208 (37) 284
Staphylococcus aureus 219c
MRSA 61 (11) 30 (4) 9 (2) 100
MSSA 51 (9) 19 (3) 9 (2) 79
Atypical pathogens 153
Chlamydia speciesd 0 (0) 13 (2) 5 (1) 18
Legionella spp. 10 (2) 70 (10) 7 (1) 87
Mycoplasma pneumoniae 1 (0) 36 (5) 7 (1) 44
Haemophilus influenzae 56 (10) 25 (3) 41 (7) 122
Pseudomonas aeruginosa 33 (6) 24 (3) 26 (5) 83
Klebsiella pneumoniae 13 (2) 16 (2) 29 (5) 58
Escherichia coli 11 (2) 23 (3) 11 (2) 45
Moraxella catarrhalis 18 (3) 6 (1) 20 (4) 44
Othere 60 (10) 66 (9) 45 (8) 171
a The proportion is relative to the number of patients not the number of specimens. Also, 171 patients were coinfected, therefore the
sum of proportions in each region is more than 100%.
b Among 284 cases, 258 (91%) were confirmed.
c Sensitivity information was not available for 41 subjects.
d All cases were C. pneumoniae except for one, which was C. psittaci.
e Other organisms isolated were: Acinetobacter, adenovirus, coagulase negative Staphylococcus, Enterobacter spp., Enterococcus
faecalis, untyped or H3N1 influenza, metapneumovirus, mixed anaerobic bacteria, nontuberculous bacteria, parainfluenza virus 1 and 4,
Proteus spp., Pseudomonas pseudomallei, respiratory syncytial virus A and B, rhinovirus/enterovirus, Salmonella spp., Serratia spp.,
and Streptococcus pyogenes.
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Canada (OR Z 0.37, 95% CI 0.18e0.72), compared to Latin
America (OR Z 0.47, 95% CI 0.27e0.82) and Europe
(OR Z 0.61, 95% CI 0.27e1.40). Further, neither overall
macrolide use in the ICU nor macrolide use among the
different risk classes differed by region (PZ 0.2 for overall
use and P Z 0.37 for differences in use by risk class).
After differences in mortality between the three regions
were found, causes for the differences were pursued with a
multivariable selection strategy (the purposeful selection
algorithm), which identified confounding variables. Prior to
fitting multivariable models, however, missing data were
imputed using multiple imputation procedures.15 This was
done to prevent potential biases resulting from associations
between missing value status and mortality or region. To
illustrate, the variable ‘antimicrobials within 8 h’ was
missing in 853 (13.4%) patients. Missing information status
for this variable was significantly associated with both re-
gion (6% missing in US/Canada, 9% missing in Europe, and
29% missing in Latin America; P-value < 0.001), and in-
hospital mortality (15% mortality among those missing in-
formation, 9% among those having information; P-
value < 0.001). Hence, failure to impute these values
would result in a marked impact of antibiotics within 8 h onthe estimated mortality differences between regions, since
a higher percentage of patients who died would be removed
in Latin America compared to the other two regions due to
missing value status.
After imputing missing data, the purposeful selection
algorithm was run separately in each of the ten imputed
datasets. For ICU patients, seven variables were selected
for inclusion in the multivariable model; H1N1 infection,
cerebrovascular disease, congestive heart failure (CHF),
elevated blood urea nitrogen (BUN), macrolide use, and
receipt of pneumococcal and influenza vaccines. After
adjustment for these variables, differences in mortality
between the regions were no longer statistically significant
(Fig. 2). The estimated OR for Europe vs. the US/Canada
was reduced from 1.31 (95% CI, 0.78e2.20) to 1.14 (95% CI,
0.66e1.96) (13%), while the OR for the US/Canada vs.
Latin America was reduced from 1.85 (95% CI, 1.22e2.20)
to 1.14 (95% CI, 0.72e1.82) (38%) and the OR for Europe vs.
Latin America was reduced from 1.41 (95% CI, 0.87e2.29)
to 1.00 (95% CI, 0.60e1.69) (29%). The most significant
covariates were H1N1 infection and macrolide use (P
value < 0.001). The remaining variables were at least
marginally significant (P value < 0.1). For patients on the
ward, eleven variables (gender, cerebrovascular disease,
Table 4 The processes of care and antimicrobial treatment regimens for 6752 patients with community-acquired pneumonia
from three regions of the world.
Region I Region II Region III P
US/Canada Europe Latin America
n Z 1834 n Z 2861 n Z 1676
No. (%) No. (%) No. (%)
Pneumococcal vaccine evaluation 551 (30) 516 (18) 80 (5) <0.001
Influenza vaccine evaluation 435 (24) 509 (18) 100 (6) <0.001
Antimicrobials within 8 ha 1219 (71) 2156 (83) 1026 (86) <0.001
Blood cultures obtained 1591 (87) 1809 (63) 979 (58) <0.001
Macrolide 845 (46) 1328 (46) 654 (39) <0.001
Fluoroquinolone 953 (52) 1114 (39) 327 (20) <0.001
b-Lactam alone 143 (8) 447 (16) 682 (41) <0.001
b-Lactam plus macrolide 670 (37) 1227 (43) 617 (37) <0.001
b-Lactam plus quinolone 178 (10) 376 (13) 176 (11) <0.001
a Missing data for 853 (13.4%) patients (USA/Canada 115 (6%), Europe 253 (9%), Latin America 485 (29%)). Percentages in cells based on
complete data.
1106 F.W. Arnold et al.CHF, parapneumonic effusion, elevated BUN, sodium and
glucose, antibiotics within 8 h, macrolide use, fluo-
roquinolone use and receipt of influenza vaccine) were
selected. After adjustment for these variables, differences
in mortality between Europe and the US/Canada were no
longer statistically significant (Fig. 3), with a reduction in
the estimated OR from 1.55 (95% CI 1.20e1.99) to 0.97
(95% CI 0.74e1.27), a percent difference of 37%. Differ-
ences between the US/Canada and Latin America, though
still statistically significant, were abated by a nearlyTable 5 The overall mortality due to community-acquired pne
regimens in three regions of the world.
Region I Reg
US/Canada Euro
n Z 1834 n Z
No. (%) No.
Overall mortality 133 (7.3)
Treatment mortality e ICU
Overall ICU mortality 44/270 (16.3) 29
Macrolide: yes 14/140 (10)
No 30/130 (23.08)
Fluoroquinolone: yes 30/138 (21.74)
No 14/132 (10.61)
b-Lactam alone: yes 4/22 (18.18)
No 40/248 (16.13) 23
Treatment mortality e ward
Overall ward mortality 89/1564 (5.69) 232
Macrolide: yes 36/705 (5.11) 82
No 53/859 (6.17) 150
Fluoroquinolone: yes 46/815 (5.64) 88
No 43/749 (5.74) 144
b-lactam alone: yes 10/121 (8.26) 6
No 79/1443 (5.47) 170similar margin (OR reduced by 30% from 1.95 (95% CI
1.48e2.57) to 1.37 (95% CI 1.01e1.87)). Conversely, how-
ever, the estimated OR between Europe and Latin America
actually increased from 1.26 (95% CI, 1.02e1.57) to 1.62
(95% CI, 1.27e2.05) (28% increase). This was primarily
attributable to the higher incidence of cerebrovascular
disease and elevated BUN in Europe relative to Latin
America. All other variables included in the model were
highly statistically significant, with the exception of anti-
biotics within 8 h, gender, and elevated sodium.umonia and mortality associated with specific antimicrobial
ion II Region III P
pe Latin America
2861 n Z 1676
(%) No. (%)
261 (9.1) 223 (13.3) <0.0001
/143 (20.28) 77/291 (26.46) 0.013
12/73 (16.44) 25/133 (18.8) 0.11
17/70 (24.29) 52/158 (32.91) 0.139
12/63 (19.05) 25/73 (34.25) 0.069
17/80 (21.25) 52/218 (23.85) 0.009
6/18 (33.33) 28/88 (31.82) 0.427
/125 (18.4) 49/203 (24.14) 0.096
/2718 (8.54) 146/1385 (10.54) <0.001
/1255 (6.53) 47/521 (9.02) 0.024
/1463 (10.25) 99/864 (11.46) <0.001
/1051 (8.37) 15/254 (5.91) 0.055
/1667 (8.64) 131/1131 (11.58) <0.001
2/429 (14.45) 81/594 (13.64) 0.203
/2289 (7.43) 65/791 (8.22) 0.022
Figure 1 Mortality in US/Canada, Europe and Latin America
for each pneumonia severity index risk class (V is highest
severity). Differences in mortality between Latin America and
the other two regions were still significant after adjustment for
disease severity (P < 0.0001 in both cases). However, differ-
ences in mortality between the US/Canada and Europe were
not statistically significant after adjustment (P Z 0.73).
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the final multivariable models individually influenced the
OR for mortality between regions is shown in Table 6. For
ICU patients, infections with H1N1 and receipt of both the
influenza and pneumococcal vaccines were important fac-
tors which lowered the OR between Latin America and the
other two regions. This is in line with Table 4, which in-
dicates that vaccination rates in Latin America were much
lower compared to the other regions. Use of a macrolide
was also important in reducing the risk between Latin
American and the other regions, though to a lesser degree.
For non-ICU patients, since Europe had the highest rates of
both cerebrovascular disease and elevated BUN, adjusting
for these factors lowered the OR between Europe and the
other two regions. Use of macrolides, quinolones, and
influenza vaccination was also important factors which
lowered the OR between Latin America and the other two
regions.
Discussion
This manuscript documents for the first time that mortality
due to CAP varies between three regions of the world. The
mortality in Latin America was greater than in Europe and
greater still than in the US/Canada despite the patients
from Latin America being younger and having lower severity
of disease. Three processes of care including obtaining
blood cultures, and providing pneumococcal and influenza
vaccines were found to be performed less often in Latin
America, which may explain why there was a difference in
mortality. A fourth process of care, antimicrobial treat-
ment, was also important. Latin America prescribed more
b-lactam antimicrobials and fewer quinolones ormacrolides than the other two regions. The best thing
about finding processes of care as a component of the
mortality difference between regions of the world is that
they are modifiable management strategies.
Prior studies comparing mortality due to CAP between
regions compared mortality rates from separate studies in
different countries. However, those comparisons can pro-
vide questionable results, since similar studies conducted
within the same region do not always agree. For example, a
survey of four studies conducted in North America
comprising a total of 1,981,362 patients demonstrated
mortality rates that varied between 4% and 13.7%.19e22 A
meta-analysis from Europe of 46 studies from 11 countries
found that the overall mortality for in- and out-patients
with CAP varied between 4% and 48%.6 In Latin America,
two relatively small studies in Argentina and Chile showed
rates of 13.3% and 12%,23,24 respectively, while more
populous data from Brazil found a rate of approximately
4%.25 The present study provides rates calculated from a
large international database of CAP, with patients obtained
from teaching hospitals in each region who were evaluated
using the same criteria. Thus, the differences in mortality
that were found between the regions are both clinically as
well as statistically significant.
Determining the reason for a disparity in mortality be-
tween regions may reveal how deaths due to CAP may be
prevented. To our knowledge, an explanation for the
observed differences in mortality between regions has not
been studied, but an editorial attributed mortality differ-
ences between regions to criteria for hospitalization.26 We
found, however, that the severity of disease was actually
highest in Europe (P < 0.001, Table 2). Also, nearly every
comorbidity recorded had a paradoxically lower incidence
in Latin America. Thus, severity of disease and comorbid-
ities did not explain the mortality difference observed be-
tween Latin America and the other regions. Adjustment for
cerebrovascular disease and elevated BUN did, however,
have a significant impact on the mortality odds ratio be-
tween Europe and the US/Canada for patients in the ward
(Table 6).
While comorbidities and disease severity were not
significantly higher in Latin America, the number of H1N1
cases was dramatically higher in Latin America compared to
the other regions. This had a significant impact on mortality
for patients in the ICU, and adjustment for this variable
reduced the mortality odds ratio between Latin America
and the US/Canada by 19% and between Latin America and
Europe by 12% (Table 6). However, H1N1 incidence was not
found to be important for explaining differences in mor-
tality between the regions for patients in the ward.
Other possible explanations for the observed differences
in mortality between regions were the difference in pro-
cesses of care between each region. Measuring processes of
care is a way to evaluate how care for CAP is delivered. In
the present study, Latin America had lower pneumococcal
and influenza vaccination rates. The vaccination recorded
in this study was especially relevant because it referred to
vaccination that occurred prior to admission, hence
potentially benefitting the patient for the hospitalization
studied. The frequency of collecting blood cultures in a
timely manner was another process of care variable that
was lower in Latin America, but data was mixed regarding
Figure 2 Adjusted odds ratios (ORs) for mortality based on multivariable logistic regression for hospitalized patients in the ICU
with community-acquired pneumonia. Adjustment was done for the following factors after variable selection using the purposeful
selection algorithm: region, comorbidities, abnormal laboratory values, antimicrobial therapy and processes of care. The model
was based on 704 patients.
1108 F.W. Arnold et al.its association with mortality probably because collecting
blood cultures is a surrogate marker for overall clinical
care.27
The antimicrobial regimen prescribed is also a process of
care variable that should be considered. Legionella pneu-
mophila, Mycoplasma pneumoniae and Chlamydia pneu-
moniae are atypical pathogens which are recommended to
be covered in all patients admitted for CAP.9 We showed
previously that fluoroquinolone, macrolide or tetracyclineFigure 3 Adjusted odds ratios (ORs) for mortality based on multiv
with community-acquired pneumonia. Adjustment was done for the
selection algorithm: region, gender, comorbidities, abnormal labor
care. The model was based on 5667 patients.use was associated with lower mortality,14 which was again
supported by these results. Though Latin America has local
guidelines recommending such antimicrobial use,28 it had
27% fewer patients who were prescribed the agents relative
to Europe, and 30% fewer patients compared to the US/
Canada. Macrolides have immunomodulatory effects, and
were used less frequently in Latin America. Our multivari-
able analysis showed that their use was significantly asso-
ciated with mortality. Prospective studies will be needed toariable logistic regression for hospitalized patients on the ward
following factors after variable selection using the purposeful
atory values/imaging, antimicrobial therapy, and processes of
Table 6 Influence of individual covariates on odds ratio (OR) estimates for ICU and non-ICU patient mortality associated with
each region, based on multivariable logistic regression models. Changes in OR for each region are provided relative to another
region as follows: Europe relative to the US/Canada, Latin America relative to the US, and Latin America relative to Europe. 95%
confidence intervals are also provided for each OR estimate.
Europe vs US/Canada Latin America vs US/Canada Latin America vs Europe
OR for region % Difference OR for region % Difference OR for region % Difference
ICU patients
Region 1.31 (0.78, 2.20) Ref 1.85 (1.22, 2.80) Ref 1.41 (0.87, 2.29) Ref
Region þ 2009 H1N1 1.20 (0.71, 2.03) 8.31 1.50 (0.97, 2.32) 18.97 1.25 (0.76, 2.05) 11.63
Region þ CHF 1.34 (0.80, 2.27) 2.77 1.84 (1.22, 2.79) 0.24 1.37 (0.84, 2.23) 2.93
Region þ CVA 1.29 (0.77, 2.17) 1.24 1.88 (1.24, 2.85) 1.59 1.45 (0.89, 2.37) 2.86
Region þ BUN 1.27 (0.75, 2.14) 2.80 1.84 (1.21, 2.79) 0.40 1.45 (0.89, 2.36) 2.46
Region þ macrolide 1.31 (0.77, 2.21) 0.04 1.79 (1.18, 2.72) 3.21 1.37 (0.84, 2.24) 3.17
Region þ pneumococcal vaccine 1.20 (0.71, 2.03) 8.29 1.53 (1, 2.36) 16.95 1.28 (0.79, 2.09) 9.44
Region þ influenza vaccine 1.23 (0.73, 2.08) 5.71 1.61 (1.06, 2.46) 12.71 1.31 (0.80, 2.13) 7.42
Non-ICU (ward) patients
Region 1.55 (1.20, 1.99) Ref 1.95 (1.48, 2.57) Ref 1.26 (1.02, 1.57) Ref
Region þ gender 1.52 (1.18, 1.96) 1.80 1.90 (1.44, 2.51) 2.48 1.25 (1.01, 1.56) 0.69
Region þ CHF 1.57 (1.22, 2.02) 1.41 2.02 (1.54, 2.66) 3.54 1.29 (1.04, 1.60) 2.09
Region þ CVA 1.34 (1.03, 1.73) 13.48 2.04 (1.54, 2.68) 4.21 1.52 (1.21, 1.91) 20.45
Region þ BUN 1.25 (0.96, 1.61) 19.44 1.84 (1.40, 2.43) 5.62 1.48 (1.18, 1.85) 17.16
Region þ sodium 1.55 (1.20, 1.99) 0.02 1.95 (1.48, 2.57) 0.03 1.26 (1.02, 1.57) 0.01
Region þ glucose 1.53 (1.19, 1.97) 0.99 1.93 (1.47, 2.54) 1.12 1.26 (1.01, 1.57) 0.13
Region þ PPE 1.51 (1.17, 1.94) 2.47 1.98 (1.51, 2.61) 1.59 1.32 (1.06, 1.64) 4.16
Region þ antibiotics wi/8 h 1.52 (1.18, 1.96) 1.90 1.91 (1.45, 2.52) 2.33 1.26 (1.01, 1.56) 0.43
Region þ macrolide 1.55 (1.21, 2.00) 0.49 1.90 (1.45, 2.51) 2.47 1.23 (0.98, 1.53) 2.94
Region þ quinolone 1.52 (1.18, 1.95) 2.03 1.86 (1.40, 2.46) 4.99 1.22 (0.98, 1.53) 3.01
Region þ influenza vaccine 1.51 (1.17, 1.94) 2.57 1.81 (1.37, 2.39) 7.41 1.2 (0.96, 1.49) 4.97
BUN Z blood urea nitrogen; CHF Z congestive heart failure; CVA Z cerebrovascular disease; PPE Z parapneumonic effusion.
CAP mortality differences in three world regions 1109determine whether this was due to immunomodulatory
effects or something else. The present study found, how-
ever, that the protective effect associated with macrolide
use was present to some degree in every region, and not
due to preferential use among lower severity patients. In
contrast to this, was the observation that fluoroquinolone
use was associated with higher mortality for patients in the
ICU, even after adjusting for disease severity. This associ-
ation was particularly evident for patients in the US/Can-
ada and Latin America, though not for European patients.
Follow-up investigations will be needed to evaluate this
seemingly paradoxical association, which is beyond the
scope of the current study.
The study was limited by its retrospective nature, and
the fact that data were obtained from chart review. In
particular, residual confounding from unmeasured cova-
riates, including other processes of care variables, differ-
ences in facilities, and other comorbidities, may have had a
significant impact on the mortality rates in each region. In
addition, treatment guidelines and antimicrobial resistance
will differ between regions, and can be difficult to ascer-
tain. However, important information can be gleaned from
the covariates which were measured, including the anti-
microbial regimens and other processes of care variables.
Another limitation was the fact that the status of death
after discharge was unknown. Although the generalizability
was broadened by the inclusion of institutions frommultiple world regions, it was narrowed at the same time to
patients cared for by pulmonologists in predominantly
teaching institutions.
There were several strengths of this study that should be
pointed out. The study used the same inclusion and exclu-
sion criteria for patients examined in three regions of the
world. CAP was also diagnosed by clinical and radiographic
criteria instead of by billing codes. The analysis was
strengthened by the robust variable selection and data
imputation strategy used for multivariable modeling.
Finally, this study had a greater representation from Latin
America compared to previous studies.Conclusion
This study found differences in mortality of patients hos-
pitalized with CAP among three world regions; US/Canada,
Europe, and Latin America. Identified factors that
contributed to these differences included incidence of H1N1
infection, elevated BUN, cerebrovascular disease, macro-
lide use, fluoroquinolone use, and vaccinations. In partic-
ular, the identified processes of care have the potential to
be modified for performance improvement. We recommend
that institutions evaluate their processes of care perfor-
mance in order to improve quality of care for CAP patients.
Future studies with an objective to identify how to
1110 F.W. Arnold et al.decrease CAP mortality in hospitalized patients, especially
in the ICU, should investigate these processes further.Acknowledgments
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